The search included MeSH terms sickle cell, hydroxyurea, and hydroxycarbamide (see Figure 1 for our search strategy). Stimulation of F-cell production in patients with sickle-cell anemia treated with cytarabine or hydroxyurea. Hydroxyurea treatment was associated with decreased mortality in symptomatic patients with SCA compared with patients receiving shorter-term hydroxyurea or no hydroxyurea (Table 2).49  Decreased mortality was also seen in 2 other cohort studies among pediatric28  and adult36  patients with SCA receiving hydroxyurea, which was not statistically significant for patients with HbSβ+-thalassemia in adults. Laboratory benefits are then sustained when children with SCA are adherent with therapy. Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Rates and risk factors. Illustration courtesy of Alice Y. Chen. The primary objectives of each trial have the opportunity to alter management and potentially increase hydroxyurea use. The pathophysiology of sickle cell anemia (SCA) arises from hemolytic anemia and acute vaso-occlusion; organ damage develops from recurrent erythrocyte sickling, chronic hemolysis, and progressive endothelial vasculopathy. Furthermore, the long-term observational studies support the sustainability of effectiveness. Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians. North West London Haemoglobinopathy Registry Group. Comparative effectiveness research should investigate outcomes of hydroxyurea treatment across diverse patient populations, including international subgroups. Means of improving adherence are also needed. Nephrol Dial Transplant 2014; 29:1211. Much has been written about the need to promote better collaborations between developed and developing nations for the treatment of patients with SCA.88,89  The new NHLBI Strategic Plan emphasizes SCA and the need for international cooperation.90  Because hydroxyurea is very inexpensive compared with most drug treatments, and generic forms of hydroxyurea have documented efficacy,91  treatment should be strongly considered for children in developing countries. Discrepancies were resolved by discussion or review by a third investigator. Hydroxyurea therapy in children severely affected with sickle cell disease. Studies reviewed herein provide increasing support of efficacy, effectiveness, and safety in both children and adults, yet indicate serious underuse for indications with the strongest evidence.8,9,58,59  Although data on toxicity associated with hydroxyurea therapy in SCD from our review are derived from case reports or series and clinical studies where toxicities were not systematically assessed, findings are consistent with the assessment in the AHRQ review.8  To highlight an example, the consideration of malignancy associated with hydroxyurea has been identified as a potential barrier to its use.60,61  The identification of 3 additional case reports of hematologic malignancies given the substantial increase in patient-years of exposure based on inclusion of more recent studies and ex vivo investigations does not provide adequate evidence of this increased risk. Describe indications for use of hydroxyurea in adults with sickle cell anemia. Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease. Long-Term Effects of Hydroxyurea Therapy in Children With Sickle Cell Disease (HUSTLE, NCT00305175) is an observational and longitudinal trial at St Jude Children's Research Hospital. This work was supported by the National Institutes of Health (U01-HL078787, R01-HL090941, U54-HL070590, N01-HB07155) and the American Syrian Lebanese Associated Charities. Preliminary report of a toxicity study of hydroxyurea in sickle cell disease. Hydroxyurea, a once daily oral medication, has emerged as … Decreased sperm counts, which did not normalize after hydroxyurea cessation, were noted in one study without a comparator group.47  After 17 years of follow-up, 94 pregnancies were reported by female and male subjects enrolled in the Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH) regardless of their HU exposure.48  Of female subjects with known HU exposure at conception or during gestation and by male subjects with known exposure at the time of conception, 16 pregnancy outcomes were reported with 8 live births (6 term and 2 premature deliveries), 5 elective abortions, and 3 spontaneous abortions. Trisha E. Wong, Amanda M. Brandow, Wendy Lim, Richard Lottenberg; Update on the use of hydroxyurea therapy in sickle cell disease. In general, trials with escalation to MTD have reported higher percentage HbF, as well as higher hemoglobin and MCV. HbF is protective against clinical severity; low-percentage HbF is associated with a higher risk of developing vaso-occlusive complications, organ damage, and early death.1,2  Accordingly, pharmacologic induction of HbF is a logical treatment goal in SCA, and recent reviews have focused on this topic.3,4  An increased white blood cell (WBC) count has also been associated with poor clinical outcomes,5,6  and more recently, elevated serum lactate dehydrogenase (LDH, reflecting intravascular hemolysis) has been associated with morbidity and mortality in SCA.7. We excluded non–English-language articles, review articles, case series, and studies with fewer than 20 patients unless the article was primarily reporting on toxicity. A cell stress signaling model of fetal hemoglobin induction: what doesn't kill red blood cells may make them stronger. Trends in pediatric sickle cell disease-related mortality in the United States, 1983-2002. Hydroxyurea for the treatment of sickle cell disease. A more novel approach, which is both gratifying and effective, is to routinely show the patient's own serial peripheral blood smears to the child and family members during outpatient clinic visits, using a multiheaded microscope.46  Because hydroxyurea does not typically have beneficial or harmful short-term effects, seeing morphologic blood cell changes from baseline to MTD (Figure 3) helps patients and families realize that hydroxyurea is actually working by improving anemia, altering morphology, and reducing circulating sickled cells. Cumulative frequency of adverse laboratory events among children and adolescents with SCA treated at MTD in the phase 1/2 HUG-KIDS study21. Hydroxyurea at 100 mg/mL is stable with efficacy in clinical trials22,28,53  and normal home use.26  Refrigeration is recommended, but liquid hydroxyurea formulations are stable at room temperature if temperature excursions do not occur; overheating reduces the drug's chemical and functional effects.74. Hydroxyurea is very safe when given by medical specialists experienced in caring for patients with sickle cell disease. Laboratory responses to hydroxyurea therapy in children with SCA are predictably beneficial yet highly variable. Figure 3 includes peripheral blood smears and laboratory results for 2 HbSS children, illustrating similarities and differences occurring during escalation to MTD. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle-cell syndromes: results of a 17-year, single center trial (LaSHS). Two sets of clinical guidelines published in 2014 address the use of hydroxyurea in SCD.56,57  Our recommendations for hydroxyurea therapy are generally aligned with those presented in the NHLBI-sponsored Evidence-Based Management of Sickle Cell Disease Expert Panel Report.56  The American Thoracic Society guidelines on the management of pulmonary hypertension in SCD recommend hydroxyurea for patients identified as being at increased risk for mortality.57  The risk assessment includes elevated tricuspid regurgitation jet velocity, elevated brain natriuretic peptide, or documented pulmonary hypertension. Anecdotes of cancer developing in young patients with SCA on hydroxyurea therapy have been reported.68-70  However, patients with SCA can develop cancer like the rest of the general population.71-73  In my own experience, 2 cases of malignancy (acute myeloid leukemia and retinoblastoma) were recognized just before starting hydroxyurea therapy, which highlights the dangers of assuming causality. QUICK TAKE Hydroxyurea Dose Escalation for Sickle Cell Anemia 02:07. All other clinicians completing this activity will be issued a certificate of participation. Strong evidence for efficacy among adults and adolescents is described, acknowledging that less strong but supportive evidence exists for infants and children. Because an elevated WBC has been associated with both morbidity and mortality of SCA,1,2,5,6  lowering the WBC count in SCA is itself potentially therapeutic. Table 2 summarizes laboratory responses to hydroxyurea, separating studies targeting MTD. SCA indicates sickle cell anemia; MCV, mean corpuscular volume; HbF, fetal hemoglobin; ARC, absolute reticulocyte count; WBC, white blood cell; ANC, absolute neutrophil count; LDH, lactate dehydrogenase; and —, not applicable. When specified, all studies initiated orally administered hydroxyurea at doses between 10 and 20 mg/kg per day. Other acute vaso-occlusive events include splenic sequestration, acute chest syndrome (ACS), and stroke, whereas others derive more from hemolytic anemia, such as pigmented bilirubin gallstones and jaundice. Pre/post comparisons in single group studies. Our recommendations are based on the evidence derived from both this current and the AHRQ systematic reviews. Impact of hydroxyurea on clinical events in the BABY HUG trial. Differences in health-related quality of life in children with sickle cell disease receiving hydroxyurea. Additional benefits of hydroxyurea treatment include salutary effects on the circulating erythrocytes (Figure 2). Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease Adult Provider Network. Clinical experience confirms that the most common short-term hydroxyurea toxicity in patients with SCA is transient and reversible myelosuppression, primarily neutropenia, although in some young patients reticulocytopenia can be dose-limiting.21,46  Marrow suppression and mild peripheral blood cytopenias represent predictable toxicities of daily hydroxyurea therapy and are actually desired effects during escalation to MTD.21,26,46  Neutropenia is the most common laboratory toxicity, but its incidence depends on the absolute neutrophil count (ANC) threshold used for toxicity and dose adjustments (usually 1.0-2.0 × 109/L); severe cytopenia is rare. The recent observation that mortality rates for older children with SCA have not changed in 20 years96  indicates the need for new approaches to disease management, especially regarding therapeutic intervention. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. Although uncommon, skin and nail pigmentation changes are cosmetic and rarely bothersome to patients or families. Bone-marrow transplantation in a patient with sickle-cell anemia. Case 1: A 29-year-old man with HbSS was hospitalized for 2 weeks with acute chest syndrome, during which time he underwent red blood cell exchange transfusion. Given the abundant evidence for laboratory and clinical efficacy of hydroxyurea therapy in children and adults with SCA, it is perhaps surprising that its mechanisms of action for HbF induction remain incompletely understood. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. Assessing the quality of reports of randomized clinical trials: is blinding necessary? conceived the study, developed outcome tables, performed data extraction and quality assessments, analyzed the data, and wrote the manuscript. Russell E. Ware; How I use hydroxyurea to treat young patients with sickle cell anemia. No longer should it be acceptable to describe children and adolescents with SCA as “doing well” just because they are pain-free or not hospitalized. The clinical efficacy of hydroxyurea for acute vaso-occlusive events was proven for adults with SCA in MSH.16  Similar efficacy has been reported in small series of children with SCA17,19,47 ; usually, the number of painful events is reduced, along with hospitalizations. "Provider barriers in sickle cell disease", "Hydroxyurea adherence and barriers”. Search for other works by this author on: Mortality in children and adolescents with sickle cell disease: Cooperative Study of Sickle Cell Disease. Children and adolescents with SCA have similar laboratory efficacy using hydroxyurea at MTD as adults. In the following sections, I summarize the published experience with hydroxyurea and then describe my personal approach to using this treatment option in young patients with SCA. Cytotoxic and genotoxic monitoring of sickle cell anemia patients treated with hydroxyurea. Anecdotes of laboratory and clinical improvement have been reported,92-94  but no recent prospective trials have been completed. Regular review of the blood smear with patients represents one effective method of maintaining or improving adherence,46  but additional creative approaches are needed. performed the article search, reviewed the articles, developed outcome tables, performed data extraction and quality assessments, analyzed the data, and wrote the manuscript; W.L. The upcoming TCD with Transfusions Changing to Hydroxyurea (TWiTCH) study is a National Heart Lung and Blood Institute (NHLBI)-sponsored, phase 3, multicenter trial that will compare monthly transfusions, the current established treatment, to daily hydroxyurea to reduce the risk of primary stroke in children with SCA and abnormal TCD velocities.55  However, in circumstances where transfusion is not available or is contraindicated, lower-quality evidence suggests use of hydroxyurea rather than no therapy.21,25  For patients with HbSC, the paucity of clinical data despite encouraging laboratory findings with hydroxyurea, does not allow us to make a recommendation for or against treatment in any clinical scenario.41. Quality of evidence and recommendations were graded based on Grading of Recommendations Assessment Development and Evaluation tool.14  Disagreements were resolved by discussion or by mediation by a third investigator. QUICK TAKE Hydroxyurea for Sickle Cell Anemia 02:09. The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial. A recommitment to sickle cell disease research. Accordingly, early treatment in young patients who have not yet developed serious or irreversible organ damage is a worthy goal. It should be emphasized, however, that expanding hydroxyurea use requires administrative planning, including adequate provider training and staffing. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience. Leukopenia, neutropenia, and thrombocytopenia were the most frequently reported side effects of hydroxyurea.6,15,20,22,28,34,36,38-40,43,45,46  These effects were generally mild and reversible with discontinuation or a decrease in hydroxyurea dose. In the case of hydroxyurea for SCA, abundant evidence has accumulated from dozens of publications documenting the efficacy of hydroxyurea in this patient population. Abstract. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Concerns about somatic and/or germ line genotoxicity underlie the potential serious late effects of hydroxyurea. Cell free hemoglobin limits nitric oxide bioavailability in sickle cell disease. Hydroxyurea is given at a fixed dose of 20 mg/kg/d for 24 months, and primary endpoints include splenic and renal function. For infants and children age 9 months or older with SCA who are asymptomatic or have infrequent pain episodes, we recommend hydroxyurea therapy (grade 1B). Hydroxyurea and sickle cell anemia: effect on quality of life. The author thanks William H. Schultz and Nicole A. Mortier for ongoing support and assistance in providing hydroxyurea treatment to more than 500 children with SCA over the past 15 years; colleagues at St Jude Children's Research Hospital for support and treatment of many young patients with SCA; Dr Thomas R. Kinney and Dr Sherri Zimmerman for early experiences and helpful discussions about hydroxyurea; Dr Clarice Reid for encouragement to pursue multicenter trials in SCA; and Dr Wendell F. Rosse for decades of guidance and mentoring toward a career in hematology. In most patients, however, 20 mg/kg/d is well tolerated, and dose escalation by 5 mg/kg/d can then occur at 8-week intervals; more rapid dose escalation may result in cumulative hematologic toxicity not initially apparent. Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014. Several multicenter randomized clinical trials are ongoing. Of the live births, no birth defects were described consistent with findings in 3 other studies reporting pregnancy outcomes24,36,47  (supplemental Table 9). Case 3: A 22-year-old woman with HbSβ+-thalassemia has frequent painful episodes and was hospitalized for the fourth time in the last 14 months. Resolution of chronic hypoxemia in pediatric sickle cell patients after treatment with hydroxyurea. In children with SCA who have ≥3 moderate to severe pain episodes in a 12-month period, we recommend hydroxyurea therapy (grade 1B). Hydroxyurea therapy offers promise for ameliorating the clinical course of children with sickle cell disease (SCD). A straightforward safety and efficacy trial of hydroxyurea in young patients with SCA in developing countries would be an important first step toward improved use of this agent. Cost-effectiveness of hydroxyurea in sickle cell anemia: Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. reviewed the articles, developed outcome tables, performed data extraction and quality assessments, analyzed the data, and wrote the manuscript; A.M.B. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. After months of planning and a thorough literature review supported by the Agency for Healthcare Research and Quality (AHRQ), the NHLBI convened a formal Consensus Development Conference in February 2008. This multicenter trial evaluated the combination of hydroxyurea and magnesium pidolate for patients with HbSC disease; CHAMPS was terminated in late 2008 because of inadequate study enrollment, but collected study data should be published in 2010. Prospective studies in young males with pretreatment and posttreatment sperm analyses will be necessary to answer this question definitively. The ideal age to initiate hydroxyurea in SCA is not yet defined, but physiologic HbF declines suggest that preventive treatment should begin early in life.87  All hematologists whose practice includes patients with SCA should begin thinking now about the logistics of expanding hydroxyurea use, anticipating that it may eventually become accepted as standard therapy to be offered to all young patients with SCA. A summary of this approach was recently published as a clinician's “user's guide”46 ; the following summarizes some salient features related to patient selection, optimal dosing, risks and benefits, and adherence. All but one RCT15  and its secondary analyses16-20  enrolled patients who had previous sickle cell–related symptoms or complications. First, education of healthcare providers must be emphasized to ensure that accurate information is available to patients and families. A systematic review of published literature from 2007 to 2013 was performed to update the evidence review sponsored by the AHRQ.8  The current literature provides a substantive increase in data on children and long-term outcomes for adults with SCD receiving hydroxyurea. Time line of hydroxyurea therapy for SCA. A survey of adult hematologists revealed that few practicing physicians felt comfortable managing hydroxyurea in adult patients.75  Hydroxyurea has not decreased the number of hospitalizations for SCA,76  despite evidence that its use is cost-effective.77  Paradoxically, the efficacy of hydroxyurea in clinical trials is quite clear, yet its effectiveness in clinical practice has not been realized. National Institutes of Health. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. We acknowledge the improvements in outcome are based on secondary outcomes from a RCT, which may or may not hold value for an individual patient. 56,57 Our recommendations for hydroxyurea therapy are generally aligned with those presented in the NHLBI-sponsored Evidence-Based Management of Sickle Cell Disease … SCA indicates sickle cell anemia; MTD, maximum tolerated dose; HUG-KIDS, prospective National Heart, Lung and Blood Institute–sponsored pediatric trial; and ALT, alanine aminotransferase. Clinical complications in severe pediatric sickle cell disease and the impact of hydroxyurea. Hydroxyurea directly inhibits the RR M2 subunit, but spontaneous regeneration of the active enzyme occurs when hydroxyurea is removed.34  For this reason, the in vivo effects of hydroxyurea on RR are predictably transient, resulting from the rapid absorption, metabolism, and excretion of hydroxyurea in mammalian systems. The online version of this article contains a data supplement. Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at http://www.medscape.org/journal/blood; and (4) view/print certificate. Mortality in sickle cell disease: life expectancy and risk factors for early death. An important challenge for healthcare providers is translating results from controlled clinical trials into everyday clinical practice. In cases 1 and 2 we recommend and in case 3 we suggest hydroxyurea therapy. Hydroxyurea therapy for sickle cell disease in community-based practices: a survey of Florida and North Carolina hematologists/oncologists. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.
Traditional Somerset Names, Maine Coon Kerpen, Rust En Vrede Restaurant, Bkh Züchter Salzburg, Smart Trike Dreirad Ersatzteile, Russisch Blau Züchter Ratingen,